(Q46210150)

20 December 2017

title

Stoppers and non-starters of disease-modifying treatment in multiple sclerosis (English)

1 reference

20 December 2017

0 references

2

J H Aarseth

1 reference

20 December 2017

author name string

N Grytten

1

1 reference

20 December 2017

K Espeset

3

1 reference

20 December 2017

G B Johnsen

4

1 reference

20 December 2017

R Wehus

5

1 reference

20 December 2017

C Lund

6

1 reference

20 December 2017

R C Haugstad

7

1 reference

20 December 2017

language of work or name

English

0 references

publication date

25 August 2012

1 reference

20 December 2017

Acta Neurologica Scandinavica

published in

1 reference

20 December 2017

volume

127

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

133-140

1 reference

20 December 2017

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Factors that influence adherence with disease-modifying therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Long-term interferon-beta treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Brain-immune communication psychoneuroimmunology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Quality of life in multiple sclerosis: measuring the disease effects more broadly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Self-perceived physical functioning and health status among fully ambulatory multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Access to and utilization of neurologists by people with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Social support and patient adherence to medical treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2012.01708.X

10.1111/J.1600-0404.2012.01708.X

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

release_cjpy3c5kivbq3lvlfb2zgbsnza

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cjpy3c5kivbq3lvlfb2zgbsnza

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

20 December 2017